Bone alkaline phosphatase is a marker of osteoblast activity. In order to study the posttranscriptional modification (glycosylation) of bone alkaline phosphatase in bone disease, we investigated the relationship between mass and catalytic activity of bone alkaline phosphatase in patients with osteoporosis and hyperthyroidism. Serum bone alkaline phosphatase aetivity was measured after lectin precipitation using the Iso-ALP test kit. Mass concentration of bone alkaline phosphatase was determined with an immunoradiometric assay (Tandem-R Ostase). In general, serum bone alkaline phosphatase mass and activity concentration correlated well. The activity : mass ratio of bone alkaline phosphatase was low in hyperthyroidism. Activation energy of the reaction catalysed by bone alkaline phosphatase was high in osteoporosis and in hyperthyroidism. Experiments with neuraminidase digestion further demonstrated that the thermodynamic heterogeneity of bone alkaline phosphatase can be explained by a different glycosylation of the enzyme.
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phosphatase, which suggests that only bone alkaline phosphatase contains N-acetylglucosamine residues in its carbohydrate moiety (13).
Two alternative techniques for quantitating bone alkaline phosphatase based on lectin precipitation and monoclonal antibodies are now available. We used both methods to investigate the relationship between mass and catalytic activity of bone alkaline phosphatase, in order to study the modification of bone alkaline phosphatase. Furthermore, the catalytic quality of bone alkaline phosphatase was evaluated by activation energy determination. Two specific groups of patients with metabolic bone disease were studied: osteoporosis and hyperthyroidism.
Materials and Methods

Subjects
Blood was collected, allowed to clot and centrifuged (1000g, 10 min, 20 °C). The supernatant serum was collected for analysis. A group of 14 healthy blood donors (age: 43 ± 14 years; 5 males, 9 females) was used s a contra l group. Thirty four patients with osteoporosis (age: 57 ± 12 years; 8 males, 26 females) were studied. The female osteoporosis group consisted of premenopausal (n = 5) and post-menopausal (n = 21) women. Eight patients (24%) had a bone fracture due to osteoporosis. All osteoporosis patients underwent an axial bone densitometry. Concomitantly, patients with hyperthyroidism (n = 78; age: 52 ± 13 years; 28 males, 50 females) were studied. The subjects with clinical suspicion or evidence of liver, biliary or renal disease and patients receiving glucocorticoid therapy were excluded frorn analysis. None of the female subjects examined was pregnant. Postmenopausal osteoporotic women were not receiving any hormonal replacement therapy at the time of study.
Measurement of total alkaline phosphatase activity
We determined alkaline phosphatase activity in serum at 37.0 °C according to the IFCC recommendation (14) (Boehringer, Mannheim, Germany) on a HITACHI 747 analyser (Boehringer, Mannheim, Germany).
(IRMA) (17) . The kit (Tandem-R Ostase, purchased from Hybritech Inc., San Diego, CA, USA) utilizes two monoclonal antibodies which are 7 times more reactive with bone alkaline phosphatase than with liver alkaline phosphatase. The assay was run overnight (incubation time: 19 h) at 2-8 °C. Measurements were made with an LKB Wallace 1261 gamma-counter (Turku, Finland).
Determination of bone alkaline phosphatase activation energy
We eluted bone alkaline phosphatase frorn the lectin precipitates by adding 100 μΐ of N-aeetylglucosamine (Sigma Chemicals Co., St Louis, MO, USA), 45 mmol/1 in saline solution (12) . Activation energy of the reaction catalysed by bone alkaline phosphatase was calculated according to the Arrhenius equation
where k] and k 2 fepresent catalytic activities at absolute temperatures, TI and T 2 , and R is the universal gas constant (8.314 J/mol •K) (18) . The Standard temperature interval for determination of the apparent activation energy was 303.14-310.14 K (30.0-37.0 °C). At both temperatures, bone alkaline phosphatase activity was measured on a HITACHI 747 analyser (Boehringer, Mannheim, Germany) using the IFCC method.
Neuraminidase treatment of bone alkaline phosphatase
Wheat germ agglutinin precipitates from blood donors were resuspended s mentioned above in N-acetylglucosamine solution and used s a bone alkaline phosphatase fraction. Samples were incubated with neuraminidase (20 U/1; EC 3.2.1.18, from Clostridium perfi-ingens\ purchased from Sigma Chemicals Co. (St Louis, MO, USA) (15) . Ten μΐ of neurarninidase were added to a 100 μΐ sample. After incubation for l h, 2 h, and 3 h at 37 °C, activation energy of bone alkaline phosphatase was evaluated and compared with the blank.
Analytical performance of bone alkaline phosphatase kits
Coefficients of Variation were calculated by analysing serum pools (total alkaline phosphatase activity: 75.7 ± 22.2 U/l, mean bone alkaline phosphatase activity: 36.8 ± 16.9 U/l, mean bone alkaline phosphatase mass concentration: 17.5 ± 7.2 μέ/l). Between-run CVs were obtained using data on 10 consecutive days.
Measurement of bone alkaline phosphatase activity by lectin precipitation
The precipitation procedure was performed with the Iso-ALP test kit (Boehringer, Mannheim, Germany). The assay utilizes wheat germ agglutinin s precipitating agent based on the principle described by Rosalki & Ying Foo (12) and simplified by Behr & Barnert (15) . The kit contains a solution of wheat germ agglutinin in acetate buffer, pH 4.5, containing 20 ml/l Triton X-100 to prevent co-precipitation of biliary alkaline phosphatase. We mixed equal amounts (100 μΐ) of lectin solution and serum. After incubation for 30 minutes at room temperature,· the mixture was centrifiiged at 10 000 g for 2.5 min. Total alkaline phosphatase and residual alkaline phosphatase activity in the. supernatant were determined. Bone alkaline phosphatase activity was calculated using the equation bone alkaline phosphatase (U/l) = 1.118 X total activity (U/l) -2.35 X supernate activity (U/l) (16 
Results
Mass and activity concentration of bone alkaline phosphatase
Within-and between-run coQfficients of Variation (CV) for the Iso-ALP kit were 3.5fend 5.9% respectively. The
Tab. l Total alkaline phosphatase activity, bone alkaline phosphatase activity, bone alkaline phosphatase mass concentration, bone alkaline phosphatase specific activity, and activation energy in the study groups Correlation between total alkaline phosphatase activity and bone alkaline phosphatase
The total serum alkaline phosphatase activities in the study groups are listed in table 1. Serum activity of bone alkaline phosphatase generally shows a good correlation with the total serum alkaline phosphatase activity: y (se- 
Activity versus mass concentration of bone alkaline phosphatase
In the blood donors, the activity : mass ratio of serum bone alkaline phosphatase at 37 °C is 2.23 ± 1.32 U^g (tab. 1). Between the osteoporosis and hyperthyroidism groups, the bone alkaline phosphatase activity : mass ratio is significantly different: 2 .41 ±2.10 U^g vs. 1.59 ± 0.77 U^g (p < 0.001). In hyperthyroidism, the bone alkaline phosphatase activity : mass ratio also differs from that of the controls (p < 0.05). For all groups, the bone alkaline phosphatase activity : mass ratio was correlated with its serum activity concentration at 37 °C: y (bone alkaline phosphatase activity: mass ratio; U^g) = 0.06 χ (serum bone alkaline phosphatase activity; U/l) + 0.214, r = 0.832, S^ = 0.76 (blood donors); y (bone alkaline phosphatase activity : mass ratio; U^g) = 0.03 χ (serum bone alkaline phosphatase activity; U/l) -l· 1.387, r = 0.761, S yx = 1.47 (osteoporosis); and y (bone alkaline phosphatase activity: mass ratio; U^g) = 0.01 χ (serum bone alkaline phosphatase activity; U/l) + 1.05, r = 0.572, Syx = 0.71 (hyperthyroidism).
Activation energy of bone alkaline phosphatase
The catalytic quality of bone alkaline phosphatase, s evaluated by determination of its activation energy, was different between the study groups. In the healthy blood donors, activation energy of the reaction catalysed by bone alkaline phosphatase was 37.7 ± 5.9 kJ/mol. As shown in table l, activation energy of bone alkaline phosphatase was increased in osteoporosis (63.3 ±11.8 kJ/mol, p < 0.001) and in hyperthyroidism (58.5 ± 18.8 kJ/mol, p < 0.05).
Effects of neuraminidase treatment on activation energy
Neuraminidase treatment of the bone alkaline phosphatase fractions obtained from 4 healthy blood donors resulted in an increase in activation energy. Prior to treatment, the activation energy of bone alkaline phosphatase was 38.0 ± 5.1 kJ/mol. Blank values (untreated samples) remained stable during the experiment. After l h incubation, the activation energy of bone alkaline phosphatase was 57.0 ± 1.2 kJ/mol (p < 0.01). After 2 h and 3 h, the activation energy rose to 66.1 ± 8.9 kJ/mol and 75.3 ±11.0 kJ/mol respectively.
Effects of age, sex, and disease
For all groups, we found no correlations between the subjects' age and total alkaline phosphatase activity, bone alkaline phosphatase activity, bone alkaline phosphatase mass concentration, bone alkaline phosphatase activity: mass ratio, or activation energy. Similarly, there were no sex differences for these quantities.
In the osteoporosis group, patients with postmenopausal osteoporosis showed higher (p < 0.05) total alkaline phosphatase activity and bone alkaline phosphatase mass (tab. 2). A history of fractures was not significantly correlated with a change in bone alkaline phosphatase values: 26.6 ± 25.1 U/l and 9.3 ± 1.9 μg/l (subgroup with bone fractures) vs. 25.5 ± 37.9 U/l and 9.2 ±3.7 μg/l for the subgroup without fractures. The axial bone densitometry (expressed s age-and sex-matched z scores) correlated well with the bone alkaline phosphatase values: y (bone alkaline phosphatase activity: U/l) = 12.84 χ (z-score) + 42.0; r = 0.634, S yx = 14.33 and y (bone alkaline phosphatase mass; μg/l) = 1.66 χ (ζ-score) + 11.9; r = 0.450, S yx = 3.02.
In the reference population, thyrotropin and FT4 values were respectively 1.68 ± 1.22 mU/1 and 14 ± 2 ng/1. In the hyperthyroidism group, thyrotropin and FT4 values were 0.02 ± 0.02 mU/1 (p < 0.001) and 29 ± 12 ng/1 (p < 0.05). According to the FT4 values, the hyperthyroidism group could be subdivided into patients with FT4 less than 18 ng/1 (n = 38), FT4 values between 18 and 30 ng/1 (n = 33), and FT4 values > 30 ng/1 (n = 7). No differences in bone alkaline phosphatase mass or activity were found between these s bgroups. No significant correlations could be calculated between FT4 vaU ues and total alkaline phosphatase activity, bone alkaline phosphatase activity, bone alkaline phosphatase mass concentration, bone alkaline phosphatase activity : mass ratio, or activation energy.
Discussion
In this study, we used two new c mmercially available methods for measuring the mass and activity concentration of bone alkaline phosphatase. Analyses were performed on a st dy group of healthy blood donors and patients with osteoporosis and hyperthyroidism, a disease associated with inetabolic bone disease (19) . In a recent multUcentre evaluation, the Iso-ALP lectin precipitation kit was found to be suitable for quantitation of serum bone alkaline phosphatase in routine analysis (16) . We comp red this method with a recently developed solid phase immunoassay (Tandem-R Ostase). In (l general, we noted that serum bone alkaline phosphatase mass and activity concentration correlate well. In our opinion, both IRMA and lectin precipitation methods offer a resolution that is equivalent, if not superior, to any other technique for separating bone alkaline phosphatase from liver alkaline phosphatase. The quality of the Separation and technical simplicity mean that both assays provide a useftil alternative for measuring bone alkaline phosphatase. However, in each of the used methods, the binding is incomplete and not completely specific.
A broad Variation from normal to very high serum bone alkaline phosphatase activities is found in the osteoporosis and hyperthyroidism groups, dependent on the clinical picture and the level of bone turnover. In patients with less drainatic skeletal involvement, any changes in bone alkaline phosphatase only make a small contribution to the circulating pool of the enzyme (1). The elevation of bone alkaline phosphatase in serum is related to bone rebuilding and not to bone resorption, and thus the levels may be normal in the early stages of osteoporosis (20) . Serum bone alkaline phosphatase increases äs the condition deteriorates and resorption and remodelling co-exist. An increase of bone alkaline phosphatase in hyperthyroidism can be explained by a direct action of thyroid hormones on osteoblasts (19) .
Using both bone alkaline phosphatase mass and activity concentration, we calculated the activity : mass ratio of the enzyme in the study groups. The activity : mass ratio of serum bone alkaline phosphatase at 37 °C is decreased in hyperthyroidism. For all study groups, the activity : mass ratio of bone alkaline phosphatase is correlated with its serum activity at 37 °C and is thus depen-; dent on the degree of bone turnover. j In the temperature interval 30 °C-37 °C, the activation energy of the reaction catalysed by bone alkaline phosphatase also differed. In both osteoporosis and hyperthy-! roidism, the activation energy of bone alkaline phospha-! tase is increased, indicating a loss of catalytic quality of the enzyme. These results suggest the existence of a thermodynanüc heterogeneity of bone alkaline phosphatase in metabolic bone disease.
Our findings are in agreement with those of several authors, who suggested the existence of a posttranslational microheterogeneity of bone alkaline phosphatase (20) . Multiple bands of bone alkaline phosphatase have been identified by isoelectric focusing of sera from heälthy adults (21, 22) . After Separation of alkaline phosphatase isoforms, using high performance liquid chromatography (HPLC) on anion exchange columns, two bone fractiohs were found in bone tissue extracts and in serum from a growing child (23) . Furthermore, one of the bone fractions was preferentially elevated in osteoporosis, osteomalacia, bone metastases and Pagei's disease (24) . Similarly, two bands of bone alkaline phosphatase were separated using affinity electrophoresis of human serum in agarose gel containing wheat germ lectin, suggesting differences in the affinity for lectin and/or the number of N-acetylglucosamine and sialic acid residues (25) . Differences in glycosylation and molecular mass have been shown between neonatal and adult forms of bone alkaline phosphatase (26) . Carbohydrate side chain heterogeneity of bone alkaline phosphatase has also been suggested in patients with Pagefs disease and hyperparathyroidism (26) . Furthermore, high performance affinity chromatography (HPAC) against wheatgerm lectin demonstrated a change in the glycosylation pattern of bone alkaline phosphatase in bone disease (27) .
In conclusion, using two alternative methods for measuring serum bone alkaline phosphatase mass and activity concentration, we were able to demonstrate a heterogeneity of bone alkaline phosphatase in metabolic bone disease.
Our findings suggest that a different posttranslational modification of bone alkaline phosphatase occurs in pathological conditions.
